Role of FDG PET/CT Scan in Head and Neck Cancer Patients


Mehrdad Bakhshayesh Karam 1 , * , Abtin Doroudinia 2 , Farahnaz Aghahosseini 3 , Fatemeh Kaghazchi 2 , Payam Mehrian 2

1 Masih Daneshvari Hospital, Pediatric Respiratory Diseases Research Center

2 Masih Daneshvari Hospital, Chronic Respiratory Diseases Research Center

3 Masih Daneshvari Hospital

How to Cite: Bakhshayesh Karam M, Doroudinia A, Aghahosseini F, Kaghazchi F, Mehrian P. Role of FDG PET/CT Scan in Head and Neck Cancer Patients, Iran J Radiol. 2017 ; 14(Special Issue):e93673. doi: 10.5812/iranjradiol.47980.


Iranian Journal of Radiology: 14 (Special Issue); e93673
Published Online: April 13, 2017
Article Type: Abstract
Received: May 14, 2019
Accepted: February 08, 2017


Background: PET/CT scan has emerging role in head and neck oncology with a few well-established indications, including: detection of unknown primary tumor site, tumor staging, radiotherapy planning, treatment response assessment and detection of recurrent disease. The purpose of this study is reporting PET/CT findings in head and neck cancer patients to emphasize on its role in head and neck oncology.

Methods: We reviewed our PET/CT date-base retrospectively and found 94 patients, referred with primary head and neck cancer. This is a descriptive report of PET/CT scan findings in head and neck cancer patients referred to MasihDaneshvari hospital since 2013 to 2016.

Results: The most common primary tumor sites were oral cavity (27%) and nasopharynx (22%). The most common indication for referral was tumor restaging (76%) including treatment response evaluation and differentiation between recurrence and post-treatment fibrosis. In 60% of patients with negative primary tumor site, PET/CT was able to detect evidence of regional or distant metastasis. PET/CT was able to localize the primary tumor site in 66% of patients with unknown primary tumor site. We had also 19 patients with primary head and neck cancer referred for initial staging, demonstrating evidence of metastasis in 66.2% of all cases.

Conclusions: Most patients are referred for restaging and demonstrate evidence of regional or distant metastasis with significant value for further treatment planning. Providing insurance coverage and familiarizing referring physicians about appropriate indications of this relatively new diagnostic modality will be to the best interest of head and neck cancer patients in long term.



  • 1.

    The references are available in PDF file.

  • © 2017, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.